Semax and Selank: The Russian Nootropic Peptides, Examined

Semax and Selank arrive with an unusual selling point: they are real medicines, just not here. Both are registered in Russia as nasal drops, one aimed at the brain after stroke, the other at anxiety. Online, that becomes "the nootropic peptides Russian doctors have used for years." The more useful question is what the studies behind them looked like, and whether any of it applies to a healthy American hoping for sharper focus or calmer nerves.

We'll take each peptide in turn, look at the quality of the evidence, cover the legal picture as of September 2026, and end with what a sensible next step looks like if you're struggling with focus or anxiety.

Where Semax and Selank come from

Both peptides came out of the Institute of Molecular Genetics of the Russian Academy of Sciences, which developed a family of short synthetic peptides modeled on fragments of natural regulatory peptides. A 2013 review by researchers from that institute (Kolomin and colleagues, Neuroscience & Medicine) describes the design idea: take a short, biologically active fragment and add a Pro-Gly-Pro tail at the end to make it more resistant to breakdown by enzymes.

• Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is built on a fragment of adrenocorticotropic hormone (ACTH), but it was designed not to have ACTH's hormonal effects on the adrenal glands.
• Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is built on tuftsin, a small peptide derived from an immune protein.

According to that review, Selank was registered by the Russian Ministry of Health in 2009 for generalized anxiety disorder and neurasthenia. Semax has been used in Russia in intranasal formulations for conditions including ischemic stroke and certain other neurological disorders.

What the Semax evidence looks like

Semax's clinical literature is centered on stroke and other brain injuries. Studies published in Russian journals, such as the Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, have examined it in patients at different stages of ischemic stroke, generally reporting favorable effects on recovery measures. Laboratory and animal work has explored its effects on brain-derived neurotrophic factor (BDNF) and on how brain tissue responds to reduced blood flow.

Several limits apply when reading that body of work:

• Size and design. Many studies are small, and not all use randomization, blinding and a placebo group in the way modern stroke trials do.
• Replication. We are not aware of large, independent, multinational trials that have confirmed the stroke findings. Stroke medicine elsewhere has not adopted Semax.
• Population. Patients recovering from a stroke are a very different group from healthy adults looking for better focus. A possible benefit in injured brain tissue says nothing reliable about cognition in an uninjured brain.

The "nootropic" claim, that Semax improves attention or memory in healthy people, rests on much thinner ground: small studies, animal research and a great deal of self-reporting online.

What the Selank evidence looks like

Selank's main clinical claim is for anxiety. One frequently cited study is Zozulia and colleagues, 2008, in the same Russian neurology and psychiatry journal, which examined Selank in patients with generalized anxiety disorder and neurasthenia and reported anxiety-reducing effects. Animal and laboratory work has explored its effects on enkephalin-degrading enzymes, GABA-related signalling and immune markers.

The same cautions apply. The trials are small by the standards of psychiatric drug development, where anxiety medicines are typically tested in multiple placebo-controlled trials involving hundreds of patients because placebo responses in anxiety are substantial. Selank has not been through that kind of program in the US or Europe.

None of this means the Russian research is fabricated or worthless. It means it is early. In the US and Europe, a drug that looked promising in a handful of small national studies would normally go on to larger trials with independent monitoring, pre-registered outcomes and published raw safety data. Semax and Selank have mostly not taken that step, so the honest description is "promising in limited studies, unconfirmed," which is a long way from "proven nootropic."

Safety: what we don't know

Russian sources generally describe both peptides as well tolerated. That's worth noting and also worth keeping in proportion. Short, small studies are not designed to detect uncommon side effects, long-term effects or interactions with other medicines.

FDA's own notes flag specific concerns. On its list of bulk substances that may present significant safety risks in compounding, FDA wrote that both Semax and Selank may pose a risk of immunogenicity for certain routes of administration because of the potential for aggregation, with peptide-related impurities also noted for Semax. In plain terms: poorly made peptide products can clump or carry impurities that the immune system reacts to.

Other gaps worth naming:

• No established data on use in pregnancy or breastfeeding.
• Little information on interactions with antidepressants, benzodiazepines, stimulants or other medicines that act on the brain.
• No reliable quality control for products sold online as "research peptides," which may not contain what the label says. See the research peptide grey market.

Where they stand legally in the US

Neither Semax nor Selank is FDA-approved. For a US pharmacy to compound a non-approved substance from bulk powder, that substance generally has to be eligible under FDA's compounding framework.

At the July 23–24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, panelists narrowly voted to recommend adding Semax to the 503A bulks list, even though FDA's own reviewers had concluded that none of the seven substances under discussion met the criteria. Advisory votes are non-binding. Adding a substance requires notice-and-comment rulemaking, and as of this writing no final rule has been reported. Legal analyses in August 2026 indicated these peptides still could not lawfully be compounded from bulk. The full story is in the July 2026 peptide vote, explained.

Selank was not among the substances voted on in July, and its status has been in flux along with other peptides FDA reviewed in 2026. Rules change; verify with FDA, and ask any prescriber to tell you exactly where a substance stands on the day you speak.

A note for athletes

The World Anti-Doping Agency's Prohibited List includes a category for non-approved substances and a category for peptide hormones and related substances. A peptide that is approved in one country but not another raises classification questions you should not try to answer yourself. Check with USADA or your sport's anti-doping organization before using either. Our guide to peptides and drug testing explains how.

What to do if focus or anxiety is the real problem

People usually search for Semax or Selank because something specific is wrong: they can't concentrate, their sleep is poor, they feel on edge most days, or their memory seems worse than it used to be. Those symptoms have causes that are worth finding. Common ones include sleep deprivation or sleep apnea, anxiety and depression, ADHD, thyroid problems, anemia, alcohol, and side effects of other medicines. Our articles on sleep and mental health and peptides for focus and memory go further.

If you'd like a straight conversation about whether any peptide makes sense for you, or whether a different route would serve you better, our peptide therapy consultations start with your history, not a product. For many people with anxiety or concentration problems, the honest answer will be that a peptide isn't the right fit, and we'll point you toward care that is.

Common questions

Are Semax and Selank legal in the US?

Neither is FDA-approved. Semax received a narrow, non-binding advisory committee recommendation in July 2026, but no final rule has been reported allowing compounding from bulk. Selank's status has also been in flux. Rules change, so check the current position with FDA or a clinician.

Do Semax or Selank actually work?

Small Russian studies reported benefits in stroke patients (Semax) and in people with anxiety disorders (Selank). Independent, large, placebo-controlled trials are lacking, and there is no strong evidence of benefit in healthy people.

Is Selank an alternative to anxiety medication?

It shouldn't be treated as one. Please don't stop a prescribed medicine without talking to the prescriber, and consider evidence-based options such as therapy and approved medicines first.

Why are they given as nasal sprays?

Peptides are broken down in the digestive tract, so swallowing them is inefficient. The nasal route avoids the gut. Our article on oral, nasal and injectable peptides explains the trade-offs.

If you have questions about a peptide you've been offered, book a consultation and we'll go through it with you honestly.